Stock Analysis
- Australia
- /
- Medical Equipment
- /
- ASX:OIL
Optiscan Imaging Full Year 2024 Earnings: AU$0.007 loss per share (vs AU$0.007 loss in FY 2023)
Optiscan Imaging (ASX:OIL) Full Year 2024 Results
Key Financial Results
- Net loss: AU$6.06m (loss widened by 39% from FY 2023).
- AU$0.007 loss per share (in line with FY 2023).
All figures shown in the chart above are for the trailing 12 month (TTM) period
Optiscan Imaging shares are up 2.6% from a week ago.
Risk Analysis
We don't want to rain on the parade too much, but we did also find 3 warning signs for Optiscan Imaging (1 makes us a bit uncomfortable!) that you need to be mindful of.
New: AI Stock Screener & Alerts
Our new AI Stock Screener scans the market every day to uncover opportunities.
• Dividend Powerhouses (3%+ Yield)
• Undervalued Small Caps with Insider Buying
• High growth Tech and AI Companies
Or build your own from over 50 metrics.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
About ASX:OIL
Optiscan Imaging
Engages in the development, manufacture, and commercialization of endomicroscopic digital imaging technology solutions for medical, translational, and pre-clinical applications in Australia, Germany, China, and the United States.